<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 12/10/2021 5:56:10 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: 05410216-c515-4df5-88c5-f947a1482cb7 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:krbp="http://www.kiromic.com/20211206" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityCentralIndexKey" id="Tc_0WxOFtDIXEqP8ml4VS4MYA_2_1">0001792581</ix:nonNumeric><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:AmendmentFlag" id="Tc_kPCiSbtzhEC9W1IX2BTIOQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="krbp-20211206.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001792581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-06</xbrli:startDate><xbrli:endDate>2021-12-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_debe0c50_f286_4f1f_9664_45ac013655af"></a><a id="BigHand_Transcription"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:DocumentType" id="Narr_-Ze5rzDp80Os7MXQXUeHMA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_DZb9tJwbxUitXLa1TD-ZRA"><span style="font-size:11pt;">December 6, 2021</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityRegistrantName" id="Narr_bU47YizFVEywIlMFinbP1Q"><b style="font-weight:bold;">KIROMIC BIOPHARMA, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_7e33a513_cb15_43df_b688_15ae2a4bc62a"></a><a id="Tc_mRxSLYp5EkOxZrGU9RDT-w_2_0"></a><a id="Tc_w_w07T5o0kyT3lBbmw-oDw_2_2"></a><a id="Tc_GozK1McehkSb882P7UN_1w_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:82.19%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:31.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:32.12%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_pUzri3UQ1EmGqvl8Rt8elA_1_0"><b style="font-size:11pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.83%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityFileNumber" id="Tc_7FAbzZ7ES0mo5vrGujcndw_1_2"><b style="font-size:11pt;font-weight:bold;">001-39619</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityTaxIdentificationNumber" id="Tc_k7zqaJRhGEWmYWIAA1JNBQ_1_4"><b style="font-size:11pt;font-weight:bold;">46-4762913</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(State or other jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">of incorporation)</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:31.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Commission</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:top;width:1.95%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:32.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(IRS Employer<br />Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityAddressAddressLine1" id="Narr_ZkwpsgeK8UKps2nPk4xmYw"><b style="font-size:11pt;font-weight:bold;">7707 Fannin Street</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityAddressAddressLine2" id="Narr_cKJcnpuAyEyrdhXDEUtnaA"><b style="font-size:11pt;font-weight:bold;">Suite 140</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityAddressCityOrTown" id="Narr_4037QF9Pwk64TfUC-MrPtw"><b style="font-size:11pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityAddressStateOrProvince" id="Narr_HoVckU8XUkWxJgroTVgHfA"><b style="font-size:11pt;font-weight:bold;">TX</b></ix:nonNumeric><b style="font-size:11pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:EntityAddressPostalZipCode" id="Narr_IJnfSBJ7F0iAzynIcBzICw"><b style="font-size:11pt;font-weight:bold;">77054</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">(Address of principal executive offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:11pt;">Registrant&#8217;s telephone number, including area code&#160;</span><b style="background-color:#ffffff;font-size:11pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:CityAreaCode" id="Narr_YFk3XtPnf0qL5_6EGolEXw"><b style="background-color:#ffffff;font-size:11pt;font-weight:bold;">832</b></ix:nonNumeric><b style="background-color:#ffffff;font-size:11pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:LocalPhoneNumber" id="Narr_gy4nk8Pf0kKSC6_jRT61Ng"><b style="background-color:#ffffff;font-size:11pt;font-weight:bold;">968-4888</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:-24pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_48f84c8c_c31f_402b_8982_8cfa1a578014"></a><a id="Tc_EqRX4-_rkEK2ewzZMWE1Ig_1_1"></a><a id="Tc_1l98NDIx7UShtN0ijoLb6Q_3_1"></a><a id="Tc_z3C-v4pWKUqjgpsoBYOlqg_5_1"></a><a id="Tc_JNGN9zgLQ0-Ma2fQVJnlKQ_7_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:84.86%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_GzCBPmvHF0moaF36gjde8w_1_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_rwWkLNLNNUSpG-uO53bsmQ_3_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc__vuk3IFrl06XDqX0qOgi9w_5_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:5.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_FIOoGlsiDEm1rRSqJeo2BA_7_0"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:94.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 0pt 18pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_d631fbf8_8edc_4753_a045_fb38a87e0ea8"></a><a id="Tc_hzYw1OGvIUOU1uAykra4Lg_1_0"></a><a id="Tc_epT9hVR12027X00B9EgokQ_1_2"></a><a id="Tc_f0g3z69kTEGtBxQDJR5hXA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:66.53%;padding:0.75pt 0pt 0.75pt 0pt;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.36%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:Security12bTitle" id="Tc_alvcFCt7XUG6nRuz2yc3Sg_2_0"><span style="font-size:11pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" name="dei:TradingSymbol" id="Tc_HZo9w_vkTkmarJ20iMgeIQ_2_2"><span style="font-size:11pt;">KRBP</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.69%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"></td><td style="vertical-align:bottom;width:39.97%;margin:0pt;padding:0pt 0pt 1.5pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_ctMuTtd1Tk6Mys5ZYSH8rA_2_4"><span style="font-size:11pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_tSgirjGiNEyW3PpyTcbBEg"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_12_6_2021_To_12_6_2021_mcGMBAsE4kadQHQapKVMYw" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_s-P1jCHtnUyto4zc5pDJAw"><span style="font-family:'Segoe UI Symbol';font-size:11pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:23.75pt;min-height:33.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_26fdfc48_3fe9_44dd_9d4d_d512176475ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><table style="background-color:#ffffff;border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.96%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#ffffff;vertical-align:top;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;5.02</b></p></td><td style="background-color:#ffffff;vertical-align:top;width:87.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:12pt 0pt 0pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</span></span>On December 6, 2021, Ignacio Nunez informed the Board of Directors of Kiromic Biopharma, Inc. (the &#8220;Registrant&#8221;) that he was resigning his position as Chief Manufacturing and Operating Officer immediately due to personal reasons. Mr. Nunez&#8217;s resignation did not involve a disagreement with the Registrant on any matter relating to the Registrant&#8217;s operations, policies or practices. &#160;On December 8, 2021, Mr. Nunez and the Registrant entered into a Separation Agreement dated as of December 6, 2021 (the &#8220;Separation Agreement&#8221;) in connection with his resignation. &#160;The Separation Agreement sets forth , among other things, the separation compensation payable to Mr. Nunez as well as the vesting terms of certain stock options and restricted stock units held by Mr. Nunez that were previously issued to him pursuant to the Registrant&#8217;s 2017 Equity Incentive Plan. &#160;The Separation Agreement also contains, among other things, certain covenants related to confidentiality and non-disparagement as well as a general release. &#160;A copy of the Separation Agreement is attached hereto as Exhibit 10.1. The foregoing description of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, which is attached hereto as Exhibit 10.1 and which is incorporated by reference into this Current Report on Form 8-K</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:11pt;padding-top:12pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibit.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-top:14pt;text-align:justify;margin:0pt;">(d) Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The following exhibit is filed herewith: </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:103.25%;"><tr style="height:1pt;"><td style="vertical-align:top;width:14.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:85.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;Exhibit No.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:11pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Description</b></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="krbp-20211206xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">Separation Agreement dated as of December 6, 2021 between Kiromic Biopharma, Inc. and Ignacio Nunez</span></a></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:14.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:85.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:23.75pt;min-height:48.25pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:76.47%;border:0;margin:30pt 11.76% 30pt 11.76%;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9ded1356_449e_4317_9f78_1215e5c0cc93"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:46.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Kiromic BioPharma, Inc.</b></p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Date: December 10, 2021</p></td><td colspan="2" style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">By:</p></td><td style="vertical-align:top;width:46.8%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="white-space:pre-wrap;"> /s/ Daniel Clark</span></p></td></tr><tr><td style="vertical-align:top;width:49.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:46.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Daniel Clark</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">Interim Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.27;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:24pt;"><td colspan="2" style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:24pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 12pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td><td colspan="2" style="vertical-align:top;width:50.07%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:24pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:14.4pt;min-height:57.6pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;"><tr><td style="vertical-align:top;width:39.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;">21538445.2<br />238823-10002</span></p></td><td style="vertical-align:top;width:21.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "krbp-20211206x8k.htm", "description": "8-K", "secsgml_size_bytes": 40541}]
{"company-data": {"conformed-name": "Kiromic Biopharma, Inc.", "cik": "0001792581", "assigned-sic": "2836", "irs-number": "464762913", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39619", "film-number": "211485263"}, "business-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054", "phone": "832-968-4888"}, "mail-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054"}, "former-company": {"former-conformed-name": "Kiromic, Inc.", "date-changed": "20191029"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
​
FORM
8-K
​
CURRENT REPORT
​
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported):
December 6, 2021
​
KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
​
Delaware
001-39619
46-4762913
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
​
7707 Fannin Street
,
Suite 140
Houston
,
TX
,
77054
(Address of principal executive offices) (Zip Code)
​
Registrant's telephone number, including area code
(
832
)
968-4888
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Securities registered pursuant to Section 12(b) of the Act:
​
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 par value
KRBP
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
​
Emerging growth company
☒
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
1
​
​
​
​
​
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers.
​
(b)
On December 6, 2021, Ignacio Nunez informed the Board of Directors of Kiromic Biopharma, Inc. (the "Registrant") that he was resigning his position as Chief Manufacturing and Operating Officer immediately due to personal reasons. Mr. Nunez's resignation did not involve a disagreement with the Registrant on any matter relating to the Registrant's operations, policies or practices.  On December 8, 2021, Mr. Nunez and the Registrant entered into a Separation Agreement dated as of December 6, 2021 (the "Separation Agreement") in connection with his resignation.  The Separation Agreement sets forth , among other things, the separation compensation payable to Mr. Nunez as well as the vesting terms of certain stock options and restricted stock units held by Mr. Nunez that were previously issued to him pursuant to the Registrant's 2017 Equity Incentive Plan.  The Separation Agreement also contains, among other things, certain covenants related to confidentiality and non-disparagement as well as a general release.  A copy of the Separation Agreement is attached hereto as Exhibit 10.1. The foregoing description of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, which is attached hereto as Exhibit 10.1 and which is incorporated by reference into this Current Report on Form 8-K
Item 9.01. Financial Statements and Exhibit.
(d) Exhibits
The following exhibit is filed herewith:
​
​
Exhibit No.
​
Description
10.1
Separation Agreement dated as of December 6, 2021 between Kiromic Biopharma, Inc. and Ignacio Nunez
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
​
​
2
​
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
​
​
Kiromic BioPharma, Inc.
Date: December 10, 2021
By:
/s/ Daniel Clark
Daniel Clark
Interim Chief Financial Officer
​
​
​
​
​
​
​
​
21538445.2
238823-10002
​
​
​